Tvardi Therapeutics, Inc. (TVRD)
NASDAQ: TVRD · Real-Time Price · USD
24.61
-0.60 (-2.38%)
At close: Jun 27, 2025, 4:00 PM
24.45
-0.16 (-0.65%)
After-hours: Jun 27, 2025, 5:55 PM EDT
Company Description
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need in the United States.
The company's lead product candidates include TTI-101, which is in Phase 2 clinical development for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in pre-clinical stage.
Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
Tvardi Therapeutics, Inc.
Country | United States |
Founded | 2017 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Imran Alibhai |
Contact Details
Address: 3 Sugar Creek Center Boulevard, Suite 525 Sugar Land, Texas 77478 United States | |
Phone | 713 489 8654 |
Website | tvarditherapeutics.com |
Stock Details
Ticker Symbol | TVRD |
Exchange | NASDAQ |
Stock Type | Common Stock |
Reporting Currency | USD |
CIK Code | 0001742947 |
CUSIP Number | 140755307 |
ISIN Number | US1407553072 |
Key Executives
Name | Position |
---|---|
Dr. Imran Alibhai Ph.D. | Chief Executive Officer and Director |
Wallace Hall Jr. | Founder, President and Director |
David J. Tweardy M.D. | Co-Founder and Scientific Advisory Board Member |
Dr. Ronald A. DePinho M.D. | Co-Founder and Chairman of Scientific Advisory Board |
Dr. Michael T. Lewis Ph.D. | Co-Founder and Scientific Advisory Board Member |
Dan Conn J.D., M.B.A. | Chief Financial Officer |
Dr. Jeffrey Larson DABT, Ph.D. | Senior Vice President of Research & Development |
Dr. John Kauh M.D. | Chief Medical Officer |
Stephen O'Brien CPA | Vice President of Finance and Corporate Controller |
Dr. Yixin Chen Ph.D. | Vice President of CMC |